Grand Pharmaceutical Group (HKG:0512) said the first patient was enrolled in its clinical study of GPN00289 in China, a temperature-sensitive embolic agent for advanced liver cancer treatment, according to a Thursday filing with the Hong Kong bourse.
The study assesses the safety and efficacy of the treatment, which combines GPN00289 drug delivery and embolization.
The company's shares were down by 1% in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.